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Abstract
Background: Despite evidence of a quite large beneficial effect of endovascular treatment (EVT) for ischemic stroke
caused by anterior circulation large vessel occlusion, many patients do not recover even after complete
recanalization. To some extent, this may be attributable to incomplete microvascular reperfusion, which can
possibly be improved by antiplatelet agents and heparin. It is unknown whether periprocedural antithrombotic
medication in patients treated with EVT improves functional outcome. The aim of this study is to assess the effect
of acetylsalicylic acid (ASA) and unfractionated heparin (UFH), alone, or in combination, given to patients with an
ischemic stroke caused by an intracranial large vessel occlusion in the anterior circulation during EVT.
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Methods: MR CLEAN-MED is a multicenter phase III trial with a prospective, 2 × 3 factorial randomized, open label,
blinded end-point (PROBE) design, which aims to enroll 1500 patients. The trial is designed to evaluate the effect of
intravenous ASA (300 mg), UFH (low or moderate dose), both or neither as adjunctive therapy to EVT. We enroll
adult patients with a clinical diagnosis of stroke (NIHSS ≥ 2) and with a confirmed intracranial large vessel occlusion
in the anterior circulation on CTA or MRA, when EVT within 6 h from symptom onset is indicated and possible. The
primary outcome is the score on the modified Rankin Scale (mRS) at 90 days. Treatment effect on the mRS will be
estimated with ordinal logistic regression analysis, with adjustment for main prognostic variables. Secondary
outcomes include stroke severity measured with the NIHSS at 24 h and at 5–7 days, follow-up infarct volume,
symptomatic intracranial hemorrhage (sICH), and mortality.
Discussion: Clinical equipoise exists whether antithrombotic medication should be administered during EVT for a
large vessel occlusion, as ASA and/or UFH may improve functional outcome, but might also lead to an increased
risk of sICH. When one or both of the study treatments show the anticipated effect on outcome, we will be able to
improve outcome of patients treated with EVT by 5%. This amounts to more than 50 patients annually in the
Netherlands, more than 1800 in Europe, and more than 1300 in the USA.
Trial registration: ISRCT, ISRCTN76741621. Dec 6, 2017.
Keywords: Ischemic stroke, Acetylsalicylic acid, Heparin, Cerebrovascular disorders, Randomized controlled trial,
Endovascular treatment, Thrombectomy, Periprocedural
Background
Despite the quite large beneficial effect of endovascular
treatment (EVT) on functional outcome after ischemic
stroke, about 50% of treated patients die or remain
dependent at 3 months [1]. These unfavorable outcomes
may not be attributable to unsuccessful recanalization
alone, as approximately one third of patients do not re-
cover even when complete recanalization is reached
early after stroke onset [2]. The high risk of a poor out-
come after complete recanalization may be partially ex-
plained by incomplete microvascular reperfusion (IMR),
which is known to negatively affect tissue recovery [3–6].
Two main causes of IMR are (I) the formation of micro-
thrombi embolized from the original proximal thrombus,
formed in situ by local platelet activation or induced by
the EVT itself through vascular endothelial damage, and
(II) the formation of neutrophil extracellular traps (NETs),
in which platelets, erythrocytes, and other particles con-
glomerate [7–10]. Microvascular reperfusion might be re-
stored by counteracting these two processes. First,
formation of microthrombi could be reduced by the ad-
ministration of a platelet aggregation inhibitor, such as
acetylsalicylic acid (ASA). Second, contrary to tissue plas-
minogen activators (tPA), unfractionated heparin (UFH)
removes histones from the chromatin fibers that form the
core of the NETs, making thrombi with a large proportion
of NETs more easily dissolvable [11, 12]. In addition, the
anticoagulant effect of UFH is also based on inactivation
of factor IIa (thrombin) and factor Xa, after binding to
and activating the enzyme inhibitor antithrombin. By in-
activating thrombin, heparin prevents fibrin formation
and also inhibits thrombin-induced activation of platelets
and of factors V and VIII [13]. It is therefore likely that in
patients treated with EVT for an intracranial large vessel
occlusion, periprocedural administration of ASA and/or
UFH could improve microvascular reperfusion. This po-
tentially leads to improved functional outcome. However,
periprocedural use of ASA and/or UFH may also increase
the risk of symptomatic intracranial hemorrhage (sICH).
There are no randomized controlled trials (RCTs) on
the effects of periprocedural treatment with platelet ag-
gregation inhibitors in ischemic stroke patients treated
with EVT [14]. The ARTIS trial focused on the effect of
acute ASA administration in alteplase eligible patients
(patients eligible for EVT were underrepresented). This
trial demonstrated that ASA increased the risk of sICH
without affecting functional outcome [15]. However, the
absolute risk of hemorrhage in this trial of 4.3% was
much lower than the 6–7% in the pivotal NINDS rtPA
trial [16] and in the SITS MOST registry [17]. The po-
tential benefits in EVT—reduce vessel wall inflammation
and microthrombi formation—are much larger than in
the ARTIS trial. A number of observational and post
hoc studies have investigated the periprocedural use of
platelet aggregation inhibitors; in several of them they
were used for indications other than acute treatment it-
self (e.g., prior use of ASA based on comorbidity) [18–
24]. The occurrence of sICH in these studies varied be-
tween 6 and 17%. ASA use during EVT is not reported
in the current stroke management guidelines [25]. Based
on the results of the post hoc analysis of the MR CLEAN
trial and results from the large observational MR
CLEAN registry, periprocedural use of ASA may be a
useful and safe adjunct to EVT [21, 24].
Although RCT data on the effect of periprocedural
UFH use in ischemic stroke patients treated with EVT
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are lacking as well [14], several studies have investigated
the use of intravenous (IV) UFH during EVT [26–29].
The occurrence of sICH in these studies varied between
5 and 12%. However, the risk of sICH appears to be out-
weighed by a higher overall chance of good functional
outcome, suggesting benefit of administering UFH
during EVT. Heparin use during EVT is not reported in
the current stroke management guidelines [25]. Never-
theless, UFH is actively being used by some neuro-
interventionists during EVT, occasionally also as part of
standard care. In the Netherlands, substantial center
variability exists regarding the use of UFH as well [30].
This underlines the equipoise about periprocedural hep-
arin use. Moreover, patients had better functional out-
comes when treated in Dutch centers that treat more
patients with UFH, without an increased risk of sICH.
Based on the pathophysiology of IMR, the theoretical and
reported expected benefits, and the reported safety profile
of the two antithrombotic drugs to be evaluated, we de-
signed an RCT to evaluate the benefits and risks of ASA
and UFH, alone, or in combination, and most importantly,
their effect on functional outcome after EVT [14].
Research question
The primary objective of the multicenter randomized
clinical trial of endovascular treatment for acute ische-
mic stroke—the effect of periprocedural medication (MR
CLEAN-MED)—is to assess the effect of periprocedural
ASA and UFH, alone, or in combination, on functional
outcome at 90 days in patients who undergo EVT for
acute ischemic stroke caused by a confirmed intracranial
large vessel occlusion in the anterior circulation.
Methods
Design
MR CLEAN-MED is a multicenter phase III trial with a
prospective, randomized, open label blinded end-point
(PROBE) design (Fig. 1). Patients are randomized to re-
ceive either IV ASA (loading dose only) or IV UFH (low
dose or moderate dose, both consisting of a loading dose
and continuous infusion for 6 h), both, or neither, as ad-
junctive treatment to EVT, in a 2 × 3 factorial design. An
overview of the treatment arms and main study proce-
dures is provided in Figs. 2 and 3. Patient inclusion
started in January 2018.
Patient inclusion and exclusion criteria
The study population will be drawn from patients with ische-
mic stroke who enter the emergency department of the EVT
center. Patients are eligible for inclusion in the MR CLEAN-
MED when they are 18 years or older, have a score of at least
2 on the National Institutes of Health Stroke Scale (NIHSS),
present with a clinical diagnosis of acute ischemic stroke,
have a non-contrast computed tomography (NCCT) or mag-
netic resonance imaging (MRI) ruling out intracranial
hemorrhage, and have a large vessel occlusion in the intra-
cranial anterior circulation (distal intracranial carotid artery
or middle [M1/proximal M2] cerebral artery) confirmed by
CT angiography (CTA) or magnetic resonance angiography
(MRA). Groin puncture should be possible within 6 h from
symptom onset or last seen well. Pretreatment with IV re-
combinant tissue plasminogen activator (rtPA) according to
national guidelines is allowed. Patients already on antiplatelet
agents before the index stroke are allowed in the trial.
Exclusion criteria for enrollment in the MR CLEAN-
MED are:
– Pre-stroke disability, which interferes with the
assessment of functional outcome at 90 days (i.e.,
pre-stroke modified Rankin Scale [mRS] score > 2);
– Treatment with rtPA, given despite one or more of
the following contra-indications: cerebral infarction
in the previous 6 weeks with residual neurological
deficit or signs of recent infarction on neuroimaging,
previous intracerebral hemorrhage within the previ-
ous 3 months, INR > 1.7, use of a direct oral anti-
coagulant (DOAC), rtPA infusion > 4.5 h after
symptom onset;
– Contra-indications for ASA or UFH;
– Heparin use in therapeutic dosages that cannot be
discontinued;
– INR > 3.0;
– Known hemorrhagic diathesis or known
thrombocytopenia (< 90 × 109/L);
– Participation in medical or surgical intervention
trials other than the current or Multicentre
Randomised trial of Acute Stroke treatment in the
Ambulance with a nitroglycerin Patch (MR ASAP,
ISRCTN99503308) [31] or A reduction in Time with
Electronic Monitoring in Stroke (ARTEMIS,
NCT02808806).
Fig. 1 Trial logo
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Eligibility criteria for participating centers
Centers should be certified or meet national quality cri-
teria for EVT to be eligible for participation in the MR
CLEAN-MED [32].
Randomization and blinding
Patients who are eligible for inclusion in the MR
CLEAN-MED will be randomized by the treating phys-
ician, before endovascular treatment is started. The
randomization procedure is computer- and web-based,
using permuted blocks. Back-up assistance by telephone
is provided. The allocation sequence has been generated
by the independent trial statistician. Randomization is
stratified for participating center and in case of partici-
pation in MR ASAP for the inclusion in the active treat-
ment arm (nitroglycerine patch group). For each patient
that withdraws before the final outcome assessment, an
additional patient will be included.
Both patient and treating physician will be aware of
the treatment allocation. This open label design was
chosen from a safety perspective to avoid potential delay
in treatments for serious adverse events (e.g., administer
IV protamine sulfate) required for unblinding of the
study intervention. Clinical outcomes, such as NIHSS,
and serious adverse events are reported by trained re-
search personnel. Trained research personnel unaware
of treatment allocation will assess information on out-
come at 3 months using standardized forms and proce-
dures during a telephone interview [33, 34]. To guarantee
unawareness of the research personnel assessing the out-
come at 3 months, they will have no access to the medical
records of the patients, instruct patients or relatives before
starting the interview not to say anything about the per-
formed procedure or the admission in the hospital, and
they will enter the outcome data in a database that is kept
separated from the main clinical database. Final assess-
ment of the mRS score at 90 days will be performed by
the outcome committee, consisting of trained investigators
blinded to the treatment allocation, based on the reports
of the telephone interview. Neuroimaging on CT, MRI,
Fig. 2 Flow of patients in the MR CLEAN-MED—in first approved protocol version. Abbreviations: ASA, intravenous acetylsalicylic acid; CTA,
computed tomography angiogram; UFH, intravenous unfractionated heparin; EVT, endovascular treatment; LD, low dose; MD, moderate dose;
MRI, magnetic resonance imaging; MRA, magnetic resonance angiography; NCCT, non-contrast computed tomography; NIHSS, National Institutes
of Health Stroke Scale. Captions: *Only to be performed if imaging at 24 hour was acquired with CT; **Blood sample drawn only in case of
regular outpatient clinic appointment within 2-6 months after intervention
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and DSA will be assessed by a core laboratory blinded to
study treatment allocation. Information concerning treat-
ment allocation will be kept separate from the 90-day
follow-up outcome database. The steering committee will
be kept unaware of the results of safety assessments and
interim analyses. An independent trial statistician will
combine data on treatment allocation with the clinical
and outcome data to report summaries of trial progress,
regular safety assessments, and interim analyses on effi-
cacy and safety to the data safety monitoring board
(DSMB).
Study treatments
The study treatments, IV ASA and/or IV UFH, should
be started directly after groin puncture, and in case no
rtPA has been administered, prior to EVT. If rtPA ad-
ministration is not finished at the time of groin punc-
ture, the study treatment should be delayed until the
moment that the infusion of the full dose of rtPA is
completed. The study treatment should however be
started before the EVT procedure has been terminated,
i.e., before the catheter has been withdrawn and the
entry location has been closed. For both study interven-
tions, IV instead of oral administration was chosen to
prevent exclusion of patients with dysphagia and to
guarantee fast uptake.
IV ASA will be administered in a single dose of 300
mg. IV UFH will be administered either in a low dose
(loading dose of 5000 IU followed by 500 IU/h × 6 h) or a
moderate dose (loading dose of 5000 IU followed by
1250 IU/h × 6 h). Study treatments will be combined to
increase the efficiency of the trial, under the assumption
of independence in mechanisms of action between study
treatments, study treatments will be combined. Accord-
ing to the 2 × 3 factorial design, the six possible combi-
nations are the following (Fig. 2): (I) no ASA and no
UFH, (II) no ASA and low-dose UFH, (III) no ASA and
moderate-dose UFH, (IV) ASA and no UFH, (V) ASA
and low-dose UFH, and (VI) ASA and moderate-dose
UFH. When the occlusion seen on CTA or MRA is no
longer present on first intracranial DSA during EVT be-
fore initiation of mechanical treatment (i.e., groin punc-
ture), and the patient has been randomized for UFH, the
UFH infusion should be continued for 6 h. In case an
Fig. 3 SPIRIT figure Abbreviations: MR CLEAN-MED, Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The
effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both or neither; ASA, intravenous acetylsalicylic acid; UFH,
intravenous unfractionated heparin; DSA, digital subtraction angiography; NCCT, non-contract computed tomography; CTA, computed
tomography angiography; MRI, magnetic resonance imaging; MRA, magnetic resonance angiography; NIHSS, National Institutes of Health Stroke
Scale; (s)ICH, symptomatic intracranial hemorrhage; mRS, modified Rankin Scale.Captions: *See trial protocol on https://www.mrclean-med.nl for
more information about the patient flow, enrollment, interventions, and assessments; **t1 = within 1 hour before groin puncture, after
randomization; t2 = after groin puncture/during EVT; t3 = after EVT; t4 = 24 hours after EVT; t5 = 5-7 days after EVT or at discharge; t6 = 90 days
after EVT; ***Informed consent: as early as deemed possible after EVT; ****ASA/UFA loading dose administered directly after groin puncture, or
prior to groin puncture in case no recombinant tissue plasminogen activator has been given, UFH continuous infusion until 6 hours after EVT;
*****Blood samples: within 1 hour before groin puncture, within 1 hour after EVT, at 24 hours after EVT, if applicable 2-6 months after EVT;
******Recanalization grade on DSA at t2, and CTA or MRA at t4
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untoward event occurs after randomization (e.g., perfor-
ation, neurological deterioration), the decision to with-
hold ASA and/or UFH is left to the discretion of the
treating physician. All patients in the study will start or
continue non-trial antithrombotic medication for sec-
ondary prevention according to local guidelines, which
mostly concerns treatment with antiplatelet agents.
Study procedures
Patients undergo assessment of the NIHSS at baseline,
24 h, and 5–7 days. Certified assessors will carry out the
NIHSS assessment. Patients will undergo NCCT and
CTA at baseline, as part of usual care. For baseline im-
aging, MRI and MRA are also permitted. Follow-up im-
aging can be performed with either NCCT and CTA at
24 h (± 12 h) and NCCT at 5–7 days or discharge, or
MRI and MRA at 24 h (± 12 h). If follow-up imaging at
24 h (± 12 h) is performed with MRI, no additional im-
aging at 5–7 days or discharge is required. The protocol
“MRI follow-up investigations” should consist of at least
diffusion weighted imaging (DWI), fluid attenuation in-
version recovery (FLAIR), T2 weighted image (T2*w),
and intracranial three-dimensional time-of-flight (3D-
TOF) MRA sequences.
The choice of post-EVT imaging modality (CT or
MRI) is left to the individual participating centers, but
the chosen modality should be adhered to during the
trial in order to prevent confounding by indication. Only
in case of contra-indications for MRI, CT imaging may
be performed instead and vice versa. The condition of
the patient should not drive the decision to deviate from
the standard imaging protocol. Follow-up imaging is not
part of usual care in every hospital.
Blood samples will be taken from patients when lo-
gistics at the participating centers allow this. Blood
samples will be drawn at the following time points:
(1) within 1 h before groin puncture, (2) within 1 h
after EVT, and (3) at 24 h after EVT, if possible dur-
ing routine blood drawings. We will also take a blood
sample if the patient has a regular (not-trial-related)
outpatient clinic appointment (2–6 months after treat-
ment). One tube EDTA (± 5 mL), one tube without
anticoagulant (± 7 mL), and two tubes citrated blood
(2.7 mL) will be drawn every time, which adds up to
no more than 20 mL. Substudies may require add-
itional blood tubes, never exceeding 20 mL per draw-
ing. If continuous venous access is available,
commonly the case in patients at time point 1, 2, and
3, this will be used. Samples will be stored at − 80 °C
for later analysis of procoagulant and genetic factors
that may interact with treatment effect. In addition,
“waste material” (i.e., retrieved thrombi and blood as-
pirated during the EVT) will be stored. All biomate-
rials will be stored for 15 years.
Deferred consent
MR CLEAN-MED will investigate an acute interven-
tion in an emergency situation concerning a life-
threatening disorder. For several ethical and legal rea-
sons, the investigators ask all patients or their repre-
sentative for written consent after the study
treatment(s) and EVT have been carried out (i.e., de-
ferred informed consent). The patient or representa-
tive will be asked to provide consent as early as
deemed appropriate and reasonable after hospital ad-
mission, ideally before upcoming study procedures
after EVT and ultimately before final outcome assess-
ment. If a patient or his/her representative refuses to
provide consent, participation in the trial will be ter-
minated immediately. Participation in MR CLEAN-
MED is voluntary, and the patient or representative
may—at any given time—withdraw informed consent
without explanation. When consent by proxy has
been obtained and the patient recovers, we will again
ask for written consent from the patient. If a patient
has died before deferred consent was obtained, the
representative will be informed about trial participa-
tion (Fig. 4).
Study outcomes
The primary outcome is the score on the modified
Rankin Scale at 90 days (± 14 days) [35]. The mRS is
the preferred disability parameter of clinical trials in
stroke [36]. The mRS is an ordinal hierarchical scale
that describes the range of disability encountered post
stroke and incorporates six categories from 0 (no
symptoms) to 5 (severe disability), and a score of 6
has been added to include “death.” Assessment of
outcome on the mRS will be performed by independ-
ent assessors, blinded to the allocated and received
study treatment.
Secondary outcomes include:
– Recanalization grade (extended Treatment In
Cerebral Ischemia [eTICI] score) on final digital
subtraction angiography (DSA) after EVT [37];
– Recanalization grade at 24 h (± 12 h), assessed with
CTA or TOF-MRA [38];
– Score on the NIHSS at 24 h and 5–7 days, or at
discharge [39];
– Follow-up infarct volume, at 5–7 days assessed with
NCCT, or at 24 h (± 12 h), assessed with DWI-MRI.
Follow-up infarct volume will be assessed with the
use of an automated, validated algorithms [40];
– All possible dichotomizations of the mRS at 90 days
(± 14 days);
– Score on the EQ-5D-5L and Barthel index at 90 days
(± 14 days) [41, 42].
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Safety outcomes include:
– Intracerebral hemorrhage according to the
Heidelberg Bleeding Classification [43];
– SICH scored according to the Heidelberg Bleeding
Classification (with the addition of sICH that led to
death and that was identified as the predominant
cause of the neurologic deterioration) [43];
– Extracranial hemorrhage requiring transfusion or
resulting in death;
– Embolization in new territory on DSA during EVT;
– Infarction in new territory within 5–7 days assessed
with NCCT or 24 h (± 12 h) assessed with DWI-
MRI;
– Death from all causes within 90 days
All imaging-related outcomes on CT, MRI, and DSA
will be assessed by an independent core laboratory
blinded to study treatment allocation. Clinical outcomes
such as NIHSS and serious adverse events are reported
by trained research personnel.
(Serious) adverse event reporting
Safety is an issue of concern as both ASA and UFH
could increase bleeding risk. Adverse events are defined
as any undesirable experience occurring to a subject
during the study, whether or not it is considered related
to the investigational product. All adverse events re-
ported spontaneously by the subject or observed by the
investigator or his/her staff will be recorded. A serious
adverse event is any untoward medical occurrence or ef-
fect that (I) results in death, (II) is life threatening (at
the time of the event), (III) requires hospitalization or
prolongation of existing inpatients’ hospitalization, or
(IV) results in persistent or significant disability or in-
capacity. The (local) investigator will report the follow-
ing SAEs occurring in the study period to the sponsor
without undue delay of obtaining knowledge of the
events: death from any cause, sICH defined according to
the Heidelberg criteria, extracranial hemorrhage, cardiac
ischemia, pneumonia, allergic reactions, and new ische-
mic stroke in a different vascular territory. Events that
result in any of the outcomes listed, according to
Fig. 4 Flow of informed consent procedure in the MR CLEAN-MED. Abbreviations: MR CLEAN-MED, multicenter randomized clinical trial of
endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both or
neither; ED, emergency department; EVT, endovascular treatment; ASA, intravenous acetylsalicylic acid; UFH, intravenous unfractionated
heparin. Captions: *The patient or representative will be asked to provide consent as early as deemed appropriate and reasonable after hospital
admission, ideally before upcoming study procedures after EVT and ultimately before final outcome assessment
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appropriate medical judgment, if no medical or surgical
intervention would have been carried out, will also be
considered a serious adverse event. Serious adverse
events that meet the aforementioned criteria will be re-
ported to the sponsor, within 24 h after coming to notice
of the (local) investigator, by making use of the ap-
propriate forms in the eCRF, which will automatically
lead to notification of the study coordinator. Elective
hospital admission will not be considered a serious
adverse event. Technical complications or vascular
damage at the target lesion such as perforation or
dissection that do not lead to clinically detectable
SAEs, and neurological deterioration not caused by
intracranial hemorrhage or new ischemic stroke, are
considered as consistent with the natural course of
the ischemic stroke and should be reported at the patient’s
90 days follow-up.
Safety registry
Due to the deferred consent procedure, the study treat-
ment will have been administered to patients prior to
obtaining informed consent. The procedure requires that
all information on patients who did not provide consent
after EVT is discarded and deleted. This may be against
the interest of patients who did provide consent, and
against the interest of the general public, as patients with
sICH and other serious adverse events might be more
likely to refuse consent for participation. Not consider-
ing these records might very well result in an underesti-
mation of the true safety and validity of the data, and it
might lead to undetected safety concerns for all consent-
ing patients in the trial. To overcome this concern, we
will register the following variables in a strictly anon-
ymized safety registry for all patients, irrespective of
whether a patient has provided written informed con-
sent: patient’s study number, study treatment, in-
hospital sICH occurrence (yes/no), and in-hospital sur-
vival status (yes/no). All other information will be com-
pletely erased from the patient’s study record in case no
consent is provided. The link to the study database will
be erased from the patient’s medical record.
Data and Safety Monitoring Board
The independent Data and Safety Monitoring Board
(DSMB) consists of a neurologist, a neuro-
interventionist, and an independent statistician. The
DSMB will meet at least annually or after inclusion
of each 300 patients (whichever comes first) to
monitor the efficacy and safety of the study treat-
ments. The DSMB will evaluate the occurrence of
unwanted effects by study treatments and by center.
During the period of patient enrollment, short safety
reports are made by the independent statistician of
the trial after the occurrence of every 5 sICHs or
after the occurrence of every 10 deaths, whichever
comes first. Depending on the results of previous
analyses, the DSMB may propose to the steering
committee to relax the criterion of 5 sICH or 10
deaths. Safety of the study treatments in terms of
sICH risk and all-cause mortality will be evaluated
based on the safety registry. Also, during the period
of patient enrollment, interim analyses on major
endpoints (including serious adverse events believed
to be due to treatment) will be supplied by the inde-
pendent statistician of the trial (annually or as soon
as possible after inclusion of 300 patients, whichever
comes first), in strict confidence, to the chairman of
the DSMB along with any other analyses that the
committee may request. In the light of the safety re-
ports and interim analyses, the DSMB will advise the
chairman of the steering committee if, in their view,
the randomized comparisons in the trial have pro-
vided both (1) “proof beyond reasonable doubt” that
for all, or for some specific types of patients, one
particular treatment is clearly indicated or clearly
contraindicated in terms of a net difference in out-
come, and (2) evidence that might reasonably be ex-
pected to materially influence patient management.
Appropriate criteria of proof beyond reasonable
doubt cannot be prespecified precisely, but a differ-
ence of at least 3 standard deviations in an interim
analysis of a major endpoint may be needed to jus-
tify halting or modifying the study prematurely. This
criterion has the practical advantage that the number
of interim analyses is of little importance. The prin-
cipal investigators (PIs), study personnel, and steering
committee will remain blinded to the treatment alloca-
tion in the dataset and to the results of the safety assess-
ments and interim analyses.
Sample size
Power was estimated by simulation [44]. For the control
arm in the study, the distribution over the 7-point mRS
was based on data of the MR CLEAN trial: mRS 0, 3%;
mRS 1, 9%; mRS 2, 21%; mRS 3, 18%; mRS 4, 22%; mRS 5,
6%; and mRS 6, 21%. For both ASA and UFH, we assume
a favorable effect with a common odds ratio of 1.27, which
corresponds to an absolute risk difference of having a
score on the mRS of 0–2 of approximately 5%. Covariate
adjustment will be used, which reduces the required sam-
ple size by approximately 25% [45, 46]. We aim to include
1500 patients, which will provide 84% power to detect a
true difference in outcome between the ASA and the con-
trol arm, and 78% power to detect a true difference in out-
come between any of the low-dose UFH, moderate-dose
UFH, and control arm (two-sided alpha = 0.05). No adjust-
ments for multiple comparisons will be made.
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Statistical analyses
The analysis and reporting of the trial will be in accord-
ance with the CONSORT guidelines [47].
The main treatment contrasts that will be analyzed
are:
– ASA vs. no ASA
– Any dose UFH vs. no UFH
In addition, as secondary analysis, we will compare:
– Low-dose UFH vs. no UFH
– Moderate-dose UFH vs. no UFH
– Low-dose UFH vs. moderate-dose UFH
All analyses will be performed according to the
intention-to-treat principle. Baseline data by treatment
allocation will be reported with standard statistical pro-
cedures, and missing values for baseline characteristics
will be reported. Missing baseline characteristics will be
imputed using multiple regression imputation. The pri-
mary effect estimate, which is the common odds ratio
for a shift on the 7-category mRS at 90 days, will be
assessed by means of an ordinal logistic regression ana-
lysis. Secondary effect estimates will be assessed by
means of linear, logistic, or ordinal logistic regression
analyses, as appropriate. Pre-specified adjustments will
be made for known prognostic variables including: age,
time from onset to door of EVT center, time from door
EVT center to groin puncture, baseline NIHSS, pre-
stroke mRS, and collateral score. Adjusted and
unadjusted estimates will be reported as a beta, odds
ratio, or common odds ratio with their 95% confi-
dence intervals. We assume the effects of ASA and
UFH to be independent, but this assumption will be
tested with a test for interaction. Before follow-up of
all included patients is completed, a statistical analysis
plan will be developed and published that specifies
the hypotheses to be tested and the more detailed
statistical methods to analyze treatment effects on second-
ary outcomes, adjustments for covariates and subgroup
analyses. We will interpret the common odds ratio as the
best estimate of an average treatment effect, and therefore,
no formal testing of the proportionality assumption is
necessary.
Data management
All MR CLEAN-MED data are entered into a web-based
trial management system that allows for edit and audit
trails, by trained local research nurses. Case report forms
can be found on the website (http://www.mrcleanmed.
nl/). Patient records are coded by a unique study num-
ber. The local investigators will keep a list showing
codes and names. Unique documents with identifying
information will be stored separately from the study
database in digital files, categorized by study number on
a secure drive system, only accessible to the study coor-
dinators. Data will be monitored for completeness,
consistency, and validity by the study coordinators
through automated data checks. Twenty-five percent of
local data are carefully reviewed against source data,
based on a pre-assessed risk evaluation and in accord-
ance with Dutch standards, by an independent monitor
performing two to three visits per year during the study
period (Additional file 1). The database will be closed
within 1 month after the last scheduled follow-up date
of the last included patient.
Study organization
MR CLEAN-MED is embedded in the Collaboration for
New Treatments of Acute Stroke (CONTRAST) consor-
tium, a nationwide collaboration of clinical and transla-
tional scientists. The CONTRAST consortium will
perform five large RCTs in stroke patients to test novel
treatment strategies, aimed at preservation of ischemic
tissue and improving outcome after stroke (Multicentre
Randomised trial of Acute stroke treatment in the Am-
bulance with a nitroglycerin Patch [MR ASAP,
ISRCTN99503308] [31]; intravenous treatment followed
by endovascular treatment versus direct endovascular
treatment for acute ischemic stroke caused by a prox-
imal intracranial occlusion [MR CLEAN-NO IV,
ISRCTN80619088]; the current study: Multicenter ran-
domized clinical trial of endovascular treatment for
acute ischemic stroke. The effect of periprocedural
medication: acetylsalicylic acid, unfractionated heparin,
both or neither [MR CLEAN-MED, ISRCTN76741621];
Multicenter Randomized Clinical Trial of Endovascular
Treatment of Acute Ischemic Stroke in The Netherlands
for Late arrivals [MR CLEAN-LATE, ISRCTN19922220];
The Dutch ICH Surgery Trial - pilot study; minimally-
invasive endoscopy-guided surgery for spontaneous in-
tracerebral hemorrhage [DIST, NTR7180]. Although MR
CLEAN-NO IV, MR CLEAN-MED, and MR CLEAN-
LATE, which all aim to improve outcome after EVT by
focusing on the optimization of EVT and the expansion
of its indication, draw from the same pool of patients
with acute ischemic stroke, there is no competition be-
tween the three trials (Fig. 5). All studies are independ-
ent clinical trials, but investigators collaborate closely
and the trials share the same data structure and format,
imaging and clinical assessment procedures, and out-
come, imaging, and SAE assessment committees. Pa-
tients enrolled in MR CLEAN-NO IV, MR CLEAN-
MED, or MR CLEAN-LATE can also participate in MR
ASAP, for which patients will be stratified.
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The MR CLEAN-MED is guided by several MR
CLEAN-MED-organized and CONTRAST-organized
committees:
The steering committee of the trial consists of all local
PIs of the participating centers. Each participating center
has two local PIs: a vascular neurologist and a neuro-
interventionist. The steering committee will meet at least
annually. Final decisions concerning protocol changes,
publication, and reporting will be made by the steering
committee. The steering committee is chaired by the cen-
tral PIs of the trial. Decisions will be made in consensus,
but if unavoidable by majority vote. Day to day conduct of
the trial will be managed by the trial coordinators, who
will be supervised by the central PIs of the trial.
The executive committee of the trial consists of the
central PIs of the trial, a representation of local PIs, in-
cluding the PIs of the two other MR CLEAN II trials,
and of the study coordinators. They meet regularly, dis-
cuss trial progress, and prepare information for the
steering committee.
The writing committee consists of the executive com-
mittee and local PIs of the five collaborating centers that
have contributed the most patients to the trial in the
first 2 years of trial execution. The task of the writing
committee is to prepare the main publication which will
be drafted by the study coordinators, supervised by the
two central PIs. Typically, the main paper will be
authored by the study coordinators, the local PIs, the
committee members, the central PIs, the coordinators of
the two other MR CLEAN trials, and data management
group, in name of all MR CLEAN-MED investigators.
Authorship has to comply with the criteria of the Inter-
national Committee of Medical Journal Editors (IMCJE
at http://www.icmje.org/) [48].
Fig. 5 Flow of patients in the acute stroke trials of the Collaboration for New Treatments of Acute Stroke (CONTRAST) consortium.
Abbreviations: MR ASAP, Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch; ED, emergency
department; DIST pilot study, Dutch Intracerebral Hemorrhage Surgery Trial - pilot study; minimally-invasive endoscopy-guided surgery for
spontaneous intracerebral hemorrhage; LVO, large vessel occlusion; IVT, intravenous thrombolysis with alteplase; MR CLEAN-MED, multicenter
randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid,
unfractionated heparin, both or neither; MR CLEAN-NO IV, intravenous treatment followed by endovascular treatment versus direct endovascular
treatment for acute ischemic stroke caused by a proximal intracranial occlusion; MR CLEAN-LATE: Multicenter Randomized Clinical Trial of
Endovascular Stroke treatment in The Netherlands for Late arrivals. Captions: *Considerations: The CONTRAST trials are independent clinical trials.
Patients included in MR ASAP may also be included in one of the other trials. We will perform pre-specified subgroup analyses to test for
interaction between the different study treatments. At the first ED (i.e., primary stroke center or participating EVT center), all patients with a
probable diagnosis of acute stroke will undergo non-invasive imaging to differentiate between cerebral infarction or intracranial hemorrhage and
to assess an intracranial LVO in the anterior circulation. When the first ED is a primary stroke center and the patient could be eligible for DIST
pilot study, MR CLEAN-MED, or MR CLEAN-LATE, the patient should be transferred to a participating EVT center. Patients arriving at a primary
stroke center first will generally not be eligible for MR CLEAN-NO IV, since IVT cannot be withheld until after patient transfer to the EVT center,
unless the perceived contraindications for IVT are not present anymore upon arrival at the EVT center. Then, inclusion in MR CLEAN-NO IV will
have priority over inclusion in other trials. Competition between the three MR CLEAN trials will not occur
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The other trial committees are not trial specific and
will be formed in collaboration with the four CON-
TRAST randomized clinical trials on acute stroke: MR
ASAP, MR CLEAN-LATE, MR CLEAN-MED, and MR
CLEAN-NO IV. These are the imaging committee, the
adverse event committee, and the outcome committee.
The committees will regularly report to the steering
committees of the involved trials.
The imaging committee is chaired by the CONTRAST
imaging work package leaders (CM and AL) and consists
of neuroradiologists from the collaborating centers.
Their task is to assess and evaluate masked baseline and
follow-up imaging, which is performed per protocol and
stored in a central web-based database (XNAT, https://
www.xnat.org/). Assessments will be stored in research
forms and entered in the clinical database, which will be
accessible to investigators after approval by the Steering
committee.
The adverse event committee consists of at least 3
members, including a neurologist and a neuroradiologist.
Their task is to oversee and review all reported serious
adverse events.
The outcome committee consists of at least 3 members,
all seasoned neurologists. Their task is to evaluate all
coded and masked structured reports of the outcome as-
sessments at 90 days of patients in the trials. This way,
we can ensure blind outcome assessment.
The investigators and collaborators of MR CLEAN-
MED are listed in the Appendix.
Strategies for improving adherence to the intervention
protocol and other study procedures and for achieving ad-
equate participant enrollment include training sessions at
all participating centers, regular newsletters and research
meetings with all collaborators, and monthly telephone
meetings with the study coordinators and central PIs of
the MR ASAP, MR CLEAN-NO IV, MR CLEAN-MED,
and MR CLEAN-LATE.
Ethical considerations
The MR CLEAN-MED protocol, including the template
informed consent forms, which can be found on http://
www.mrcleanmed.nl/ has been approved for the
Netherlands by the central medical ethics committee
and research board of the Erasmus MC University Med-
ical Center, Rotterdam, the Netherlands (MEC-2017-
366) before the start of the trial. The study will be con-
ducted according to the principles of the Declaration of
Helsinki (7th revision, October 2013), ICH-GCP, the
Dutch Medical Research Involving Human Subjects Act
(WMO) and when it becomes applicable in accordance
with regulations of other countries with participating cen-
ters. The current manuscript is based on protocol version
1.6 (April 2019). The most up-to-date approved trial
protocol including protocol version and amendments can
be found on the website (http://www.mrcleanmed.nl/).
Trial status
The initial approval of the MR CLEAN-MED trial proto-
col by the ethical board covered approval of patient en-
rollment in the four organizing centers of four stroke
trials performed by the CONTRAST collaboration. For
logistic reasons, approval was given for 16 other centers
at a later stage. The first patient was enrolled in the MR
CLEAN-MED in January 2018. The DSMB did not re-
port any safety concerns following the first three safety
assessments. However, after receipt of the 4th safety re-
port on April 16, 2019, the DSMB recommended unani-
mously that the steering committee should consider
stopping the moderate-dose UFH arm of the trial, but
should continue the other arms of the trial. The grounds
for stopping this specific arm were related to safety ra-
ther than efficacy. The steering committee of the trial
has acted upon receiving this advice and directly stopped
inclusion in the moderate-dose UFH arms of the trial.
At the time point of receiving the DSMB’s advise, 137
patients were enrolled in the trial, of which 46 patients
in the moderate-dose UFH arm. No patients have been
included in the moderate-dose UFH arm after receipt of
the DSMB recommendation. After consulting the med-
ical ethics committee, the inclusion of patients in the
ASA and low-dose UFH arms was continued the next
day (Fig. 6). Meanwhile, patients, family, and representa-
tives were contacted personally and regulatory bodies
were notified. In the 4th safety report, the DSMB advised
to further evaluate the efficacy and safety of the
moderate-dose UFH arm, which will be compared to
the blinded data of the other arms. Results from this
analysis have been reported on scientific meetings
and will be submitted for publication [49, 50]. On
May 31, 2020, a total of 5 Dutch and 5 French sites
agreed to participate in MR CLEAN MED, and 441
patients were included in the trial by 13 enrolling
centers. Recruitment is expected to be completed by
the end of 2021. More information about the MR
CLEAN-MED, including progress of the trial and
participating centers can be found on the website
(http://www.mrcleanmed.nl/).
Discussion
MR CLEAN-MED—a multicenter RCT investigating the
effect of periprocedural ASA and UFH, alone or in com-
bination, in patients with acute ischemic stroke who
undergo EVT within 6 h after symptom onset for a con-
firmed intracranial large vessel occlusion in the anterior
circulation—is being conducted in the framework of the
CONTRAST consortium (https://www.contrast-consor-
tium.nl/) in continuation of the MR CLEAN trial [51]
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and the MR CLEAN-Registry [52] to further improve
outcomes for patients who undergo EVT. This trial will
provide evidence whether adjunctive periprocedural
therapy with ASA and/or UFH leads to improved micro-
vascular reperfusion and better outcomes despite a pos-
sibly increased risk of sICH in these patients.
Other ongoing trials
Next to the MR CLEAN-MED, there are currently no
other ongoing trials investigating the effect of ASA and/
or UFH in patients with acute ischemic stroke who will
undergo EVT.
Expected benefit
The trial design is pragmatic and the trial results should
be generalizable and representative of clinical practice.
We chose to include the most unselected patient popu-
lation—in which EVT was proven effective—in the MR
CLEAN-MED, so that the study treatments may be
extrapolated to the broadest and most diverse patient
group, if proven effective.
This implies that both ASA and UFH as an adjunctive
treatment to EVT may be given to a broad selection of
patients undergoing EVT. We consider both ASA and
UFH suitable for evaluation with a phase 3 RCT, as both
study treatments are well known and have been used for
similar endovascular procedures in the fields of neur-
ology and cardiology for several decades. There is exten-
sive clinical experience with the use of both agents, they
are both widely accessible, cheap, easy to administer,
and for UFH the activity is easily reversed—also in ad-
junction to EVT. Therefore, if a significant treatment ef-
fect of ASA and/or UFH will be proven in the MR
CLEAN-MED, both treatments could also be easily im-
plemented in clinical practice on a large scale. Consider-
ing the low costs of this medication, we expect the
treatment to be cost-effective as well. Consequently, a
substantial number of patients could potentially profit
from these treatments.
Fig. 6 Flow of patients in the MR CLEAN-MED—modification after the recommendation of the DSMB to stop recruiting patients for moderate-
dose unfractionated heparin. Abbreviations: ASA, intravenous acetylsalicylic acid; CTA, computed tomography angiogram; UFH, intravenous
unfractionated heparin; EVT, endovascular treatment; LD, low dose; MD, moderate dose; MRI, magnetic resonance imaging; MRA, magnetic
resonance angiography; NCCT, non-contrast computed tomography; NIHSS, National Institutes of Health Stroke Scale. Captions: *Only to be
performed if imaging at 24 hour was acquired with CT; **Blood sample drawn only in case of regular outpatient clinic appointment within 2-6
months after intervention
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Limitations and concerns
The underlying assumption of independence of study
treatment effect on the primary outcome in a random-
ized trial with a factorial design is important, because it
allows analysis of treatment effects separately for both
treatments. We consider the assumption reasonable for
the main effects on functional outcome, as the under-
lying mechanisms differ (inhibition of platelet activation
versus interference with coagulation factors thrombin,
factor Xa, other proteases through activation of anti-
thrombin and by degrading NETs). However, we will
analyze whether the assumption of independence of the
effect of aspirin and heparin on the occurrence of sICH
is true. If the assumption of independence is violated, we
will analyze stratified treatment effects.
Inherently to the acute setting of the trial and necessity
for deferral of consent, bias could have been introduced by
selective patient refusal (e.g., in case of a poor clinical con-
dition). The trial will provide generalizable results regarding
safety of the study treatments, as all randomized patients
will be registered in the safety registry providing informa-
tion on in-hospital sICH risk and mortality. It is not pos-
sible to register mRS scores of randomized patients who
refused to provide consent out of respect of each patient’s
autonomy. Therefore, the estimate of the treatment effect
on the primary outcome should be interpreted in the light
of the refusal rate. As we expect the refusal rate to be low,
we anticipate that the impact on the generalizability of the
trial’s results will be low.
Based on the available literature, upon start of the trial,
we considered the risk of sICH associated with the ad-
ministration of both UFH doses and/or ASA acceptable
in the light of expected improved functional outcomes.
This was also reflected by the systematic use of UFH for
this indication in a substantial number of centers in the
Netherlands and in other countries [28–30]. Moreover,
experimental work showed that the immediate use (< 6
h) of ASA and/or UFH could add to improvement of
outcomes by preventing or limiting microvascular occlu-
sion within the regions of ischemic injury [5, 53, 54].
The risk of sICH risk remains an important concern in
the MR CLEAN-MED. We monitor the occurrence of
sICH strictly by performing regular safety assessments in
consultation with the DSMB. We also evaluate the safety
of the study medication in terms of sICH rate and all-
cause mortality in the anonymized safety registry, which
includes all treated patients.
There is no clear evidence which UFH dose and regi-
men may be most effective and safe. We had chosen to
investigate the efficacy of two different UFH doses to
evaluate a possible dose effect. The protocol for the dif-
ferent dosages of UFH are based on findings from the
PROACT I and II and IST trials and on experience in
later thrombectomy studies [28–30, 55, 56]. The
PROACT I trial compared intra-arterial recombinant
pro-urokinase in combination with IV UFH to IV UFH
alone for patients with a visible middle cerebral artery
occlusion. The bleeding risk in the UFH alone arm of
7.1% seemed acceptable for both the high dose (100 IU/
kg bolus followed by 1000 IU/h continuous infusion for
4 h) and low-dose arms (dose 2000 IU bolus followed by
500 IU/h continuous infusion for 4 h). In the high-dose
UFH group of the International Stroke Trial (IST), in
which patients received 12,500 IU UFH subcutaneous
twice daily up to 14 days, the absolute risk of sICH was
low (2.0%) [56]. These results suggested that the low and
moderate doses of UFH in MR CLEAN-MED would
both be associated with acceptable risks. Nevertheless,
the DSMB recommended the steering committee to stop
enrollment in the moderate-dose UFH arm of the trial
based on safety concerns. Therefore, this arm has been
removed from the trial and safety and outcome results
will be reported separately, without compromising the
blinding of investigators to results of the other trial
arms. As inclusion in the moderate-dose UFH arm of
the trial has been permanently discontinued, we will
now only investigate treatment effects for ASA and for
low-dose UFH.
The steering committee of the MR CLEAN-MED ad-
vised per July 19, 2019, for reasons of homogeneity
among centers to limit intra-arterial flushing of the
sheath with UFH during EVT up to 2500 IU per liter.
Deferral of consent
In MR CLEAN-MED, we use a deferred consent proced-
ure. The primary reason for this approach is that in is-
chemic stroke, acute treatments are based on the “time
is brain” principle, in order to reduce loss of brain tissue
as time progresses. In patients treated with EVT, each
hour delay to reperfusion is associated with an increase
in absolute risk of disability of 6–7% [1]. First of all, ex-
perience in MR CLEAN indicates that a proper informed
consent procedure takes more than 1 h, even when a
legal representative is involved. This would lead to an
unacceptable delay, considering the time-dependent ef-
fect of EVT. Second, most patients with acute neuro-
logical deficits (such as impaired consciousness or
aphasia) are not capable of decision making before en-
rollment in a trial. In the MR CLEAN Registry, 80 to
96% of the acute ischemic stroke patients eligible for
EVT were in retrospect considered to lack decision-
making capacity at admission, based on neurological
symptoms potentially interfering with their capacity to
decide about trial participation [57]. Exclusion of these
patients might lead to selection bias and reduced
generalizability of the trial results. Lastly, the decision-
making capacity for trial participation in an emergency
situation is also reduced by stress and by the complexity
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and volume of the provided information. Thus, the use
of the deferred consent procedure is likely to increase
patient enrollment and to reduce selection bias. How-
ever, if a substantial number of patients or representa-
tives object to enrollment after EVT, this could actually
contribute to a different kind of selection bias, particu-
larly if this disproportionally concerns patients with ad-
verse events and poor clinical outcome. Postponing
consent seems tolerated by patients and their relatives in
several clinical studies and trials [58–65]. However, a
substudy of the ESCAPE trial (the Endovascular Treat-
ment for Small Core and Anterior Circulation Proximal
cOcclusion with Emphasis on Minimizing CT to Recan-
alization Times) showed that the majority of patients or
their representatives disagreed with the use of deferred
consent [66]. Yet, none of the patients enrolled with
deferred consent in this trial withdrew consent later, and
patients agreed with the conditions used to justify
deferred consent procedures. A separate substudy
within the CONTRAST consortium, in the form of a
survey, will be carried out to further elucidate the ac-
ceptability of the deferred consent procedure in acute
stroke trials.
Conclusion
MR CLEAN-MED is a pragmatic randomized clinical trial
with a PROBE design. ASA and UFH are well known and
available everywhere. When one or both of the study
treatments show the anticipated effect on outcome, we
will be able to improve outcome of patients treated with
EVT by 5%. This amounts to more than 50 patients annu-
ally in the Netherlands, more than 1800 in Europe, and
more than 1300 each year in the USA [67, 68].
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event; sICH: Symptomatic intracranial hemorrhage; UFH: Unfractionated
heparin; WMO: Medical Research Involving Human Subjects Act (in Dutch:
Wet Medisch-wetenschappelijk Onderzoek met Mensen)
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